Intranasal COVID vaccine will enter Phase-1 trials in Jan 2021 : Bharat Biotech

Hyderabad, Dec 9,  Bharat Biotech Chairman and Managing Director Dr Krishna
Ella said its intranasal Covid-19 vaccine will enter phase-I trials in January 2021.
We have tied up with Washington University School of Medicine in St.Louis for a novel
“chimp-adenovirus” (Chimpanzee adenovirus), single-dose intranasal vaccine
for COVID-19 and the clinical trial process is also going to be faster, Dr Krishna Ella said during a virtual chat with Bengaluru-based Biocon Limited Chairperson Kiran Mazumdar at the TiE Global Entrepreneurship Summit on Tuesday night. On the pricing, he said Indian vaccines will be much cheaper when compared to other countries.
In conversation with Ms Kiran Mazumdar, on delivering the vaccine : the big opportunity, Dr.
Krishna Ella said India is one of the best Vaccine Industries in the world. One in every three children is vaccinated by Indian Vaccine Industry, he added. In the past, R and D was not so much as it is in the Vaccine industry, he said and thanks to Pandemic, the industry got good recognition. India has the experience of polio immunization.
But the number is small, just 125 million. Now in the case of the Corona, it is 7bn adults, which
is a huge challenge, he said. We as manufacturers safety is our priority. Safety is the most important in the pandemic. Among different platforms based on which vaccines are manufactured, we are working on inactivated
vaccines, Dr Krishna Ella said. Speaking on the deployment, he shared with Ms Mazumdar that we need to vaccinate 1.3 billion people and they need to be vaccinated twice. So, we need 2.6 billion syringes and needles and we are worried about the pollution these devices generate, he pointed out. The double doses of vaccine with a gap of one month in between may add more complexity to the distribution, the Bharat Biotech Chairman explained.
Besides that, he said, it is the largest ever vaccination program in the history of mankind.
Another huge challenge will be the availability of medical devices such as auto disposable
syringes, needles required for the delivery of the vaccine, Dr Krishna Ella said, adding that while
demand is more, the supply is not in commensuration with the demand as companies have been
working with far fewer resources